HHS Part B Plan Gets Pharma's Attention, But Savings Target May Be Too High
Regeneron analysis of policy's potential impact on Eylea signals that MA plans will face overwhelming challenge to achieve 20% savings in Part B.
You may also be interested in...
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.
ICER Hemophilia Gene Therapy Reviews Show Clear ‘Net Health Benefit’ But Caution On Patient, Payer Fronts Given Upfront Costs
Restrictive interpretations of FDA labels for BioMarin and CSL Behring products by payers could signal slow launch of gene therapies seeking to supplant existing treatments.